TP53 also plays critical roles in DAPK1-induced cell death,30, 31 and in human breast cancers the epigenetic suppression of DAPK1 expression and mutational inactivation of TP53 occur in a mutually exclusive manner,43 supporting the notion that DAPK inactivation in breast cancers might contribute to attenuation of TP53-dependent drug actions. Here, DAPK1 is linked to breast carcinoma.